Mer­ck KGaA, Mil­li­pore­Sig­ma make in­vest­ments in the US and Chi­na man­u­fac­tur­ing

Mer­ck KGaA an­nounced a pair of man­u­fac­tur­ing ex­pan­sions in the US and Chi­na that aim to in­crease the pro­duc­tion of test­ing ma­te­ri­als and cell cul­tures.

The Ger­man drug­mak­er last week an­nounced that it ex­pects to ex­pand its man­u­fac­tur­ing ca­pac­i­ty for pro­duc­ing high­ly-pu­ri­fied reagents used for qual­i­ty con­trol and test­ing at its site in Nan­tong, Chi­na. It plans to in­vest €70 mil­lion ($78.1 mil­lion) in build­ing a new reagent pro­duc­tion plant there that will cov­er 40,000 square me­ters or about 430,000 square feet. Once com­plet­ed, the fa­cil­i­ty will in­crease its reagent out­put by around sev­er­al thou­sand tons.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER